<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04842487</url>
  </required_header>
  <id_info>
    <org_study_id>B2020-052-01</org_study_id>
    <nct_id>NCT04842487</nct_id>
  </id_info>
  <brief_title>R2-CHOP in Untreated DEL-DLBCL：An Open-lable，Multicenter，Phase II Study</brief_title>
  <official_title>Lenalidomide Combined With Anti-CD20 Monoclonal Antibodies-CHOP in Untreated Diffuse Large B-Cell Lymphoma Patients With MYC and BCL2 Co-expression : An Open-lable，Multicenter，Phase II Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sun Yat-sen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sun Yat-sen University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To assess the efficacy and safety of lenalidomide combined with rituximab, vincristine,&#xD;
      doxorubicin, cyclophosphamide, and prednisone (r2-chop) in the initial treatment of&#xD;
      DEL-DLBCL. The primary endpoint is the complete response rate, and the second endpoints are&#xD;
      survival time (OS and PFS) and overall response rate.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 10, 2021</start_date>
  <completion_date type="Anticipated">December 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 30, 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Complete response rate</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>The complete response rate</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>PFS was defined as time from study registration to first disease progression or death whichever occurred first, otherwise subject data were censored at time last known disease free.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>Up to three years</time_frame>
    <description>OS was defined as time from study registration to death, and otherwise censored at time last known alive.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective Remission Rate</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>CR+PR</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>DLBCL</condition>
  <arm_group>
    <arm_group_label>Treatment arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Lenalidomide：25mg po QN,D1-10&#xD;
Rituximab: 375mg/m2, ivdrip, D1&#xD;
CTX: 750mg/m2, iv or ivdrip, D1&#xD;
THP: 50mg/m2, iv or ivdrip, D1&#xD;
VCR： 1.4 mg/m2 , iv（max：2mg）, D1&#xD;
Pred: 60mg/m2, po, D1-5</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>R2-CHOP(Lenalidomide,Rituximab,cyclophosphamide，hydroxyldaunorubicin，Vincristine，Prednisone）)</intervention_name>
    <description>Lenalidomide：25mg po QN,d1-10 Rituximab: 375mg/m2, ivdrip, d1 Cyclophosphamide: 750mg/m2, iv or ivdrip, d1 Hydroxyldaunorubicin: 50mg/m2, iv or ivdrip, d1 Vincristine： 1.4 mg/m2 , iv（max：2mg）, d1 Prednisone: 60mg/m2, po, d1-5 every 3 weeks was a course of treatment</description>
    <arm_group_label>Treatment arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with MYC and BCL2 co-expression Diffuse Large B-Cell Lymphoma diagnosed by&#xD;
             histopathologyImmunohistochemistry confirmed that the positive expression rate of&#xD;
             BCL-2≥50% and c-Myc≥ 40%.&#xD;
&#xD;
          -  Male or female patients: 18-80 years old.&#xD;
&#xD;
          -  ECOG physical condition score: 0-2 points for patients.&#xD;
&#xD;
          -  IPI score≥3.&#xD;
&#xD;
          -  Patients have not received any anti-tumor therapy such as radiotherapy, chemotherapy,&#xD;
             targeted therapy or stem cell transplantation.&#xD;
&#xD;
          -  In those patients with at least one evaluable or measurable lesion meeting Lugano 2014&#xD;
             criteria, the evaluable lesion was: 18F fluorodeoxyglucose / positron emission&#xD;
             tomography (18FDG / PET) examination showed that the uptake of lymph nodes or&#xD;
             extranodal areas was increased (higher than that of liver) and pet and / or computed&#xD;
             The features of tomography (CT) were in accordance with lymphoma. The measurable&#xD;
             lesions were nodal lesions with a length of &gt; 15 mm or extranodal lesions with a&#xD;
             length of &gt; 10 mm, accompanied by an increase in 18FDG uptake. There was no measurable&#xD;
             lesion and the uptake of 18FDG was increased.&#xD;
&#xD;
          -  Patients with good function of main organs, i.e. one week before admission, met the&#xD;
             following requirements: WBC &gt;= 3.5×10^9 / L, NEU≥1.5×10^9/L, Hb &gt;= 80g / L, PLT &gt;= 100&#xD;
             ×10^9 / L; heart and liver functions were normal (total bilirubin &lt;= 1.5 times of&#xD;
             normal value, ALT and AST &lt;= 2.5 times of normal value), renal functions were normal&#xD;
             (serum creatinine &lt;= 1.5 times of normal value), and coagulation function was not&#xD;
             abnormal.&#xD;
&#xD;
          -  LVEF≥50%, measured by echocardiography.&#xD;
&#xD;
          -  No other tumor-specific concomitant therapy has been administered (including&#xD;
             steroids).&#xD;
&#xD;
          -  Pregnant women of childbearing age must have a pregnancy test (serum or urine) within&#xD;
             14 days before enrollment and the result is negative, and they are willing to use&#xD;
             reliable methods of contraception during the test.&#xD;
&#xD;
          -  Patients have no other serious diseases in conflict with this clinical trial&#xD;
             protocols.&#xD;
&#xD;
          -  The subjects who volunteer to join the study and sign the informed consent form, have&#xD;
             good compliance and cooperate with the follow-up.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Other types of DLBCL: Diffuse large B-cell lymphoma associated with chronic&#xD;
             inflammation, lymphomatoid granulomatosis, Primary mediastinal (thymic) large B-cell&#xD;
             lymphoma, ALK-positive large B-cell lymphoma, Primary effusion lymphoma, Burkitt&#xD;
             lymphoma, High-grade B-cell lymphoma(including High-grade B-cell lymphoma, NOS,&#xD;
             High-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements), B-cell&#xD;
             lymphoma, unclassifiable, with features intermediate between DLBCL and classic Hodgkin&#xD;
             lymphoma, Primary diffuse large B-cell lymphoma of the CNS, EBV-positive diffuse large&#xD;
             B-cell lymphoma.&#xD;
&#xD;
          -  Transformed DLBCL (transformed DLBCL from follicular lymphoma, chronic lymphocytic&#xD;
             leukemia/small B lymphocytic lymphoma), Diffuse large B-cell lymphoma with secondary&#xD;
             involvement of the central nervous system (SCNS-DLBCL).&#xD;
&#xD;
          -  Other malignancies within the past 5 years except for carcinoma of the cervix or basal&#xD;
             or squamous cell carcinomas of the skin.&#xD;
&#xD;
          -  Major surgical procedures (excluding diagnostic surgical procedures) performed in the&#xD;
             past 2 months.&#xD;
&#xD;
          -  Prior treatment for NHL, concomitant chemotherapy, radiotherapy immunotherapy,&#xD;
             monoclonal antibody therapy, surgical treatment (except for diagnostic surgery and&#xD;
             biopsy).&#xD;
&#xD;
          -  Prior treatment with cytotoxic drugs or anti-CD20 monoclonal antibody for other&#xD;
             conditions (e.g. Rheumatoid arthritis)&#xD;
&#xD;
          -  Prior treatment with thalidomide, lenalidomide, or other drugs.&#xD;
&#xD;
          -  Prior treatment with any monoclonal antibody within the preceding 3 months. Prior&#xD;
             treatment with live (attenuated) virus vaccine within the preceding 1 month.&#xD;
&#xD;
          -  Patients taking hematopoietic cytokines within 2 weeks before enrollment.&#xD;
&#xD;
          -  Patients with suspected active or latent TB infections.&#xD;
&#xD;
          -  Patients with known active bacterial, viral, fungal, mycobacterium, parasitic or other&#xD;
             infections (excluding fungal nail infection) or any serious systemic infections&#xD;
             requiring intravenous antibiotic treatment or hospitalization (excluding neoplastic&#xD;
             fever) in the 4 weeks prior to enrollment.&#xD;
&#xD;
          -  Other serious conditions that may limit patients participation in the trial, such as&#xD;
             Uncontrolled diabetes, Severe cardiac insufficiency (NYHA grade II or above), Acute&#xD;
             coronary syndrome in the last 6 months, Coronary revascularization includes stent&#xD;
             implantation, coronary artery bypass surgery, and other cardiac and vascular related&#xD;
             procedures in the last 6 months, severe arrhythmia (including frequent ventricular&#xD;
             premature beats, ventricular tachycardia , fast atrial fibrillation/ atrial flutter,&#xD;
             severe bradycardia), Uncontrolled high blood pressure(&gt;150/100mmHg), gastric&#xD;
             ulcer(gastric ulcers were at risk of perforation), Active autoimmune disease, Severe&#xD;
             hypertension, Severe respiratory disease(obstructive pulmonary disease or history of&#xD;
             bronchospasm).&#xD;
&#xD;
          -  Any contraindication of the CHOP drugs, including previously received anthracycline&#xD;
             antibiotics; Patients with diabetes cannot tolerate prednisone therapy.&#xD;
&#xD;
          -  Patients had a history of alcohol abuse or drug abuse.&#xD;
&#xD;
          -  Allergic physique or known sensitivity or allergy to the active ingredient, excipient,&#xD;
             murine products, heterologous proteins of any drug used in this treatment(including&#xD;
             CHOP).&#xD;
&#xD;
          -  Patients with serious mental illness.&#xD;
&#xD;
          -  Patients who are unable to comply during the trial and/or follow-up phase.&#xD;
&#xD;
          -  The researchers considered the patients unsuitable for the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>April 8, 2021</study_first_submitted>
  <study_first_submitted_qc>April 12, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 13, 2021</study_first_posted>
  <last_update_submitted>April 12, 2021</last_update_submitted>
  <last_update_submitted_qc>April 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sun Yat-sen University</investigator_affiliation>
    <investigator_full_name>Li Zhiming</investigator_full_name>
    <investigator_title>chief physician</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Rituximab</mesh_term>
    <mesh_term>Vincristine</mesh_term>
    <mesh_term>Lenalidomide</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>YES</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

